Biomedical Aspects of Drug Targeting

1. Front Matter

   Pages i-xvii

   PDF

2. General Principles of Drug Targeting

   1. Front Matter

      Pages 1-1

      PDF

   2. Strategies and Means for Drug Targeting: An Overview

      • Vladimir P. Torchilin

      Pages 3-26

   3. Biological Barriers for Drug Targeting

      • Vladimir R. Muzykantov

      Pages 27-44

3. Cardiovascular Targeting

   1. Front Matter

      Pages 45-45

      PDF

   2. Targeting the Pathological Myocardium

      • Ban-An Khaw

      Pages 47-67

   3. Targeting Atherosclerotic Plaques

      • Ban-An Khaw

      Pages 69-83

   4. Thrombus Targeting of Plasminogen Activators and Anticoagulants

      • Karlheinz Peter, Christoph Bode

      Pages 85-106

   5. Tissue-Specific Pharmacodelivery and Overcoming Key Cell Barriers in Vivo: Vascular Targeting of Caveolae

      • Lucy A. Carver, Jan E. Schnitzer

      Pages 107-128

   6. Targeting Pulmonary Endothelium

      • Vladimir R. Muzykantov

      Pages 129-148

   7. Targeting Inflammation

      • Jonathan R. Lindner, Alexander L. Klibanov, Klaus Ley

      Pages 149-172

   8. Intravascular Re-Targeting of Viral Vectors

      • Paul N. Reynolds, Sergei M. Danilov

      Pages 173-190

4. Tumor Targeting

   1. Front Matter

      Pages 191-191

      PDF

   2. Polymer-Drug Conjugates: Targeting Cancer

      • Ruth Duncan

      Pages 193-209

   3. Enhanced Permeability and Retention (EPR) Efect: Basis for Drug Targeting to Tumor

      • Hiroshi Maeda

      Pages 211-228

   4. Ligand-Directed Destruction of Tumor Vasculature

      • Sophia Ran, Michael Rosenblum, Philip E. Thorpe

      Pages 229-248

   5. Tumor Necrosis Treatment and Imaging of Solid Tumors

      • Alan L. Epstein, Leslie A. Khawli, Peisheng Hu

      Pages 249-274

   6. Targeted Apoptosis: Antibodies Linked to RNA Damaging Agents

      • Susanna M. Rybak, Michaela Arndt, Juergen Krauss, Dianne L. Newton, Bang K. Vu, Zhongyu Zhu

      Pages 275-290

   7. Immunotoxins and Antibody-Drug Conjugates for Cancer Treatment

      • Victor S. Goldmacher, Walter A. Blättler, John M. Lambert, Ravi V. J. Chari

      Pages 291-309

5. Targeting to the Brain

   1. Front Matter

      Pages 311-311

      PDF

Drugs usually have no natural affinity for the cells, tissues and organs where therapeutic effects are needed, which frequently results in low efficiency and unwanted side effects. This concern is even more profound when using highly potent and cytotoxic anticancer drugs or specific agents, such as enzymes and genetic materials, since their effective and safe action requires precise cellular or even sub-cellular addressing in the target organ. To meet safety, efficiency and specificity requirements, drugs somehow must be targeted to the sites of their expected therapeutic action. The idea of the "magic bullet," or drug targeting, proposed by Erlich a century ago, generates great and continuously growing interest in biomedical, industrial and financial circles. This book is focused on the strategies designed to target therapeutic or diagnostic agents to the disease sites. In an attempt to include in this volume the set of chapters reflecting both traditional and emerging areas of drug targeting, we have contacted many leading scientists in the field asking for their contributions. Their responses were most favorable and encouraging. As a result, we have succeeded in assembling a series of outstanding contributions reflecting practically all the key areas of drug targeting. The final structure of this book is as follows.

• Epoxidharze
• Retention
• Tumor
• apoptosis
• endothelium
• imaging
• polymer
• tissue

• School of Medicine, University of Pennsylvania, Philadelphia, USA

  Vladimir Muzykantov

• School of Pharmacy, Northeastern University, Boston, USA

  Vladimir Torchilin

Policies and ethics